Latest Conference Articles

Elizabeth Thiele, MD, PhD, pediatric neurologist/epileptologist, discusses the impact of tuberous sclerosis complex on children.

Jacqueline A. French, MD—professor of neurology, NYU Comprehensive Epilepsy Study Consortium, president, The Epilepsy Study Consortium—discusses how the new ILAE definition of epilepsy can improve patient outcomes.

Not planning pregnancy in women with epilepsy could lead to fetal malformations.

Elizabeth Thiele, MD, PhD, pediatric neurologist/epileptologist, discusses symptoms of tuberous sclerosis complex and the role early detection plays in disease prognosis.

For the first time, the new International League Against Epilepsy (ILAE) seizure classifications were presented at the American Epilepsy Society conference during the Annual Fundamentals Symposium: The New Definition and Classification of Epilepsy on Friday, December 2, 2016.

The definition of epilepsy has been updated by the International League Against Epilepsy.

Speakers discuss the state of epilepsy care around the world at the AES conference.

Elizabeth Thiele, MD, PhD--pediatric neurologist/epileptologist, director, The Carol and James Herscot Center for Children and Adults with TSC, Massachusetts General Hospital--discusses tuberous sclerosis complex.

The report examines changing areas that will impact pharmacists.

ASHP’s 2016 Midyear Clinical Meeting is the largest gathering of clinical pharmacists in the world.

The holidays are just around the corner, but that’s not the only exciting thing about this time of year. ASHP’s 2016 Midyear Clinical Meeting is coming up, and Pharmacy Times is on site covering it.

Baricitinib significantly improved patient-reported outcomes in individuals with RA.

New drugs for psoriatic arthritis discussed during a session at the ACR/ARHP conference.

At the Annual Meeting of the American College of Rheumatology in Washington, DC, several experts presented their progress in harnessing technology to help teenagers and young adults manage their juvenile arthritis.

Study compares the safety and efficacy of sarilumab with adalimumab in patients who cannot tolerate methotrexate.

An ACR session focused on the Sunshine Act and health care transparency.

Sarilumab shows promise on circulating biomarkers of bone and joint destruction in patients with rheumatoid arthritis who had shown an inadequate response to methotrexate.

Patients with rheumatoid arthritis who demonstrate a less-than-adequate response to a tumor necrosis factor inhibitor can be treated with another disease-modifying antirheumatic drug.

Regulatory perspectives presented at ACR on biosimilars entering the market convey the importance of crafting antibodies to our own purposes.

New guidelines for rheumatoid arthritis treatment discussed at ACR conference.

ACR session reinforces the need for new research about how the genome, epigenome, and other factors play a role in rheumatoid arthritis.

There is building consensus that multiple sclerosis and rheumatoid arthritis display similar autoimmune genetic pathways.

Clinicians who marry technical skills with humanities can see their patients and themselves in the larger context of family, society, history, politics, and economics.

Using data and bioinformatics could hold the key to numerous treatment options.

Anti-tumor necrotic factor drugs could help delay hip deterioration in patients with ankylosing spondylitis.

Patients who live with rheumatoid arthritis do not die from swollen joints but face twice the risk of suffering a heart attack or stroke.

Telehealth broadly is about creating care connections across boundaries, care that encourages patients’ independence, prevention and wellness; and care that can be leveraged for needed interventions. If we get telehealth right we can reduce impact of what we know is a growing health workforce shortage and concurrently create a healthier, more engaged patient base.

The 12-biomarker test is gaining acceptance among rheumatologists and was recently added to a clinical guideline.